Goldman Sachs Maintains Buy on Bristol-Myers Squibb, Lowers Price Target to $69
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Chris Shibutani has maintained a 'Buy' rating on Bristol-Myers Squibb (NYSE:BMY), but lowered the price target from $81 to $69.

October 30, 2023 | 12:43 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Goldman Sachs has maintained a 'Buy' rating on Bristol-Myers Squibb but lowered the price target from $81 to $69.
While the 'Buy' rating is maintained, the lowering of the price target could indicate a potential decrease in the short-term value of the stock. However, the impact is likely to be neutral as the 'Buy' rating suggests that the stock is still expected to perform well in the long run.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100